Page 841 - Read Online

Franco et al. Hepatoma Res 2018;4:74 I http://dx.doi.org/10.20517/2394-5079.2018.94 Page 15 of 18

qualitative analysis. AIDS Behav 2008;12:244-54.
103. Butt G. Stigma in the context of hepatitis C: concept analysis. J Adv Nurs 2008;62:712-24.
104. Zickmund S, Ho EY, Masuda M, Ippolito L, LaBrecque DR. “They treated me like a leper”. Stigmatization and the quality of life of
patients with hepatitis C. J Gen Intern Med 2003;18:835-44.
105. Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with hepatitis C virus: a systematic review and narrative
synthesis of qualitative literature. Can J Gastroenterol Hepatol 2017;2017:3268650.
106. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, et al. Global epidemiology of hepatitis B and hepatitis C in people who
inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
107. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013;10:553-62.
108. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since
onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-109.
109. Morris MD, Shiboski S, Bruneau J, Hahn JA, Hellard M, et al. Geographic differences in temporal incidence trends of hepatitis C
virus infection among people who inject drugs: the InC3 collaboration. Clin Infect Dis 2017;64:860-9.
110. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection drug use and hepatitis C virus infection in young adult injectors: using
evidence to inform comprehensive prevention. Clin Infect Dis 2013;57:S32-8.
111. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, et al. Hepatitis C virus infection epidemiology among people who inject drugs
in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014;9:e103345.
112. Committee on a National Strategy for the Elimination of Hepatitis B and C; Board on Population Health and Public Health Practice;
Health and Medicine Division; National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of
hepatitis B and C in the United States: phase one report. Available from: https://www.ncbi.nlm.nih.gov/pubmed/?term=Eliminating+th
e+public+health+problem+of+hepatitis+B+and+C+in+the+United+States%3A+phase+one+report. [Last accessed on 28 Nov 2018]
113. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, et al. Increases in hepatitis C virus infection related to injection drug use
among persons aged ≤ 30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012. MMWR Morb Mortal Wkly Rep
2015;64:453-8.
114. Suryaprasad AG, White JZ, Xu F, Eichler BA, Hamilton J, et al. Emerging epidemic of hepatitis C virus infections among young
nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 2014;59:1411-9.
115. Van Handel MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, et al. County-level vulnerability assessment for rapid dissemination of
HIV or HCV infections among persons who inject drugs, United States. J Acquir Immune Defic Syndr 2016;73:323-31.
116. Harris AM, Iqbal K, Schillie S, Britton J, Kainer MA, et al. Increases in acute hepatitis B virus infections - Kentucky, Tennessee, and
West Virginia, 2006-2013. MMWR Morb Mortal Wkly Rep 2016;65:47-50.
117. Iversen J, Grebely J, Catlett B, Cunningham P, Dore GJ, et al. Estimating the cascade of hepatitis C testing, care and treatment among
people who inject drugs in Australia. Int J Drug Policy 2017;47:77-85.
118. Butler K, Day C, Sutherland R, van Buskirk J, Breen C, et al. Hepatitis C testing in general practice settings: a cross-sectional study of
people who inject drugs in Australia. Int J Drug Policy 2017;47:102-6.
119. van Santen DK, van der Helm JJ, Lindenburg K, Schim van der Loeff M, Prins M. HIV and hepatitis C treatment uptake among
people who use drugs participating in the Amsterdam cohort studies, 1985-2015. Int J Drug Policy 2017;47:95-101.
120. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: a review. Int J Infect Dis 2016;49:47-58.
121. Ingiliz P, Martin TC, Rodger A, Stellbrink HJ, Mauss S et al. HCV reinfection incidence and spontaneous clearance rates in HIV-
positive men who have sex with men in Western Europe. J Hepatol 2017;66:282-7.
122. Salazar-Vizcaya L, Kouyos RD, Zahnd C, Wandeler G, Battegay M, et al. Hepatitis C virus transmission among human
immunodeficiency virus-infected men who have sex with men: modeling the effect of behavioral and treatment interventions.
Hepatology 2016;64:1856-69.
123. Dore GJ. Hepatitis C treatment as prevention among HIV infected men who have sex with men: feasible? Hepatology 2016;64:1834-6.
124. Martin TC, Singh GJ, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: a pragmatic
approach. Hepatology 2015;61:1437.
125. Hagan H, Jordan AE, Neurer J, Cleland CM. Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who
have sex with men. AIDS 2015;29:2335-45.
126. Abravanel F, Métivier S, Chauveau M, Péron JM, Izopet J. Transmission of HCV NS5A inhibitor-resistant variants among HIV-
infected men who have sex with men. Clin Infect Dis 2016;63:1271-2.
127. Pineda JA, Núñez-Torres R, Téllez F, Mancebo M, García F, et al. Hepatitis C virus reinfection after sustained virological response in
HIV-infected patients with chronic hepatitis C. J Infect 2015;71:571-7.
128. Young J, Rossi C, Gill J, Walmsley S, Cooper C, et al. Risk factors for hepatitis C virus reinfection after sustained virologic response
in patients coinfected with HIV. Clin Infect Dis 2017;64:1154-62.
129. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, et al. Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving
opioid agonist therapy: a randomized trial. Ann Intern Med 2016;165:625-34.
130. Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, et al. Hepatitis C reinfection after sustained virological response. J Hepatol
2016;64:1020-6.
131. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, et al. The natural history of hepatitis C virus infection: host, viral, and
environmental factors. JAMA 2000;284:450-6.
132. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, et al. Protection against persistence of hepatitis C. Lancet 2002;359:1478-83.
133. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, et al. Incidence and prevalence of hepatitis C in prisons and other closed
settings: results of a systematic review and meta-analysis. Hepatology 2013;58:1215-24.
134. UNSW. National prison entrants’ bloodborne virus and risk behaviour survey report 2004, 2007, 2010, and 2013 . Available from: